Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2018-03-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
西南证券股份有限公司关于召开公司“15华邦债”2018年第一次债券持有人会议的通知（更新后）
Regulatory Filings Classification · 95% confidence The document is a detailed notice for a bondholders' meeting regarding the company's 2015 bond issuance. It includes meeting logistics, voting procedures, and attachments such as the agenda, voting forms, and proxy forms. The content focuses on convening a bondholders' meeting to discuss and vote on a specific proposal related to the company's debt and guarantees. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual report. The document is not a report itself but a formal notification and procedural guide for a bondholders' meeting. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement related to bondholder meetings and voting procedures, not a financial report or other specific filing type.
2018-03-26 Chinese
西南证券股份有限公司关于召开公司“15华邦债”2018年第一次债券持有人会议通知更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding the notice for a bondholders' meeting of a specific bond issuance ('15 华邦债') by 华邦生命健康股份有限公司. It corrects the bondholder registration date and reiterates details about the meeting time, place, and voting procedures. The document is short (1259 characters) and serves as a formal notice correction rather than a full report or financial statement. It does not contain financial results, management discussion, or audit information. It is not a report publication announcement since it is a correction to a meeting notice. The content fits best under a regulatory announcement related to bondholder meetings and corrections, which falls under Regulatory Filings (RNS).
2018-03-26 Chinese
西南证券股份有限公司关于召开公司“14华邦01”2018年第一次债券持有人会议通知更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding a previously issued notice for a bondholders' meeting of Huabang Life Health Co., Ltd. It corrects the bondholder registration date and reiterates details about the meeting time, place, and voting procedures. The document is short (1274 characters) and serves to amend a prior meeting notice rather than presenting financial data, management discussion, or results. It is not a report, earnings release, or regulatory filing of financial results. It is an announcement related to a bondholders' meeting, specifically a correction to a meeting notice. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories.
2018-03-26 Chinese
关于以集中竞价交易方式回购公司股份的预案（修订稿）（已取消）
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares through centralized bidding. It includes specifics about the repurchase price, quantity, purpose, funding source, authorization procedures, and expected impact on financial metrics and shareholder structure. The text references relevant laws and regulations governing share repurchases and includes independent director opinions and board resolutions. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is a formal announcement of a share buyback plan, which fits the definition of a Transaction in Own Shares (POS) filing. The document length and content confirm it is not a brief notice or a report publication announcement but a substantive disclosure of a share repurchase plan.
2018-03-23 Chinese
关于对深圳证券交易所问询函的回复公告（已取消）
Capital/Financing Update Classification · 95% confidence The document is a reply announcement from Huabang Life Health Co., Ltd. to an inquiry letter from the Shenzhen Stock Exchange. It discusses details about stock option incentive plans for subsidiaries, including the determination of exercise prices, expected management expenses, and the impact on financial data. It also covers a share repurchase plan with specific price and amount details. The document is structured as a formal announcement responding to regulatory questions rather than a full financial report or audit. It contains no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a certification or officer attestation, so it is not Regulatory Filings (RNS). The document is also not a simple notice of report publication. The content focuses on clarifying regulatory inquiries about stock option plans and share repurchase proposals, which fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes (stock options and share buybacks). The document length is 3629 characters, which is relatively short but contains substantive information about financing activities, not just a brief announcement. Therefore, the most appropriate classification is CAP with high confidence.
2018-03-23 Chinese
西南证券股份有限公司关于召开公司“15 华邦债“2018年第一次债券持有人会议的通知（已取消）
Regulatory Filings Classification · 95% confidence The document is a detailed notice about a bondholders' meeting for the "15 华邦债" bond issued by 华邦生命健康股份有限公司. It includes information about the meeting's time, place, voting procedures, eligibility, and agenda items. The agenda includes a proposal regarding not requiring the company to repay debt early or provide guarantees. The document also contains attachments such as the proposal text, attendance confirmation, voting ballot, and proxy authorization form. This is a formal notification to bondholders about convening a bondholders' meeting and the related voting process, not a financial report or earnings release. It is not an announcement of voting results but a notice to convene and conduct the meeting. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and notification that does not fit other specific categories.
2018-03-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.